99 related articles for article (PubMed ID: 15564292)
61. Histogenesis of colonic tumours in mice induced by dimethyl hydrazine.
Haase P; Cowen DM; Knowles JC
J Pathol; 1973 Jan; 109(1):Px. PubMed ID: 4719759
[No Abstract] [Full Text] [Related]
62. Imaging colon cancer development in mice: IL-6 deficiency prevents adenoma in azoxymethane-treated Smad3 knockouts.
Harpel K; Leung S; Rice PF; Jones M; Barton JK; Bommireddy R
Phys Med Biol; 2016 Feb; 61(3):N60-9. PubMed ID: 26758693
[TBL] [Abstract][Full Text] [Related]
63. Histamine metabolism and CD8(+) T cell infiltration in colon adenomas.
Boér K; Darvas Z; Bösze S; Schwelberger H; Baki M; Bélai F; Pál Z; Falus A
Inflamm Res; 2004 Mar; 53 Suppl 1():S83-4. PubMed ID: 15054631
[No Abstract] [Full Text] [Related]
64. Erratum to: Inhibition of TRPM7 suppresses cell proliferation of colon adenocarcinoma in vitro and induces hypomagnesemia in vivo without affecting azoxymethane-induced early colon cancer in mice.
Huang J; Furuya H; Faouzi M; Zhang Z; Monteilh-Zoller M; Kawabata KG; David Horgen F; Kawamori T; Penner R; Fleig A
Cell Commun Signal; 2017 Sep; 15(1):31. PubMed ID: 28893271
[No Abstract] [Full Text] [Related]
65. Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity.
Finetti F; Travelli C; Ercoli J; Colombo G; Buoso E; Trabalzini L
Biology (Basel); 2020 Dec; 9(12):. PubMed ID: 33271839
[TBL] [Abstract][Full Text] [Related]
66. Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.
Hidalgo-Estévez AM; Stamatakis K; Jiménez-Martínez M; López-Pérez R; Fresno M
Front Pharmacol; 2020; 11():533. PubMed ID: 32410997
[TBL] [Abstract][Full Text] [Related]
67. Raging the War Against Inflammation With Natural Products.
Attiq A; Jalil J; Husain K; Ahmad W
Front Pharmacol; 2018; 9():976. PubMed ID: 30245627
[TBL] [Abstract][Full Text] [Related]
68. Eicosanoid signaling in carcinogenesis of colorectal cancer.
Wang Y; Wang W; Sanidad KZ; Shih PA; Zhao X; Zhang G
Cancer Metastasis Rev; 2018 Sep; 37(2-3):257-267. PubMed ID: 29858741
[TBL] [Abstract][Full Text] [Related]
69. Implications of chemokine receptors and inflammatory lipids in cancer.
Rolin J; Maghazachi AA
Immunotargets Ther; 2014; 3():9-18. PubMed ID: 27471696
[TBL] [Abstract][Full Text] [Related]
70. Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells.
Chen SX; Du SY; Wang YT; Zhao HC; Zhang YL; Yao L
Tumour Biol; 2016 Jan; 37(1):323-9. PubMed ID: 26211005
[TBL] [Abstract][Full Text] [Related]
71. The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin.
Simper MS; Rundhaug JE; Mikulec C; Bowen R; Shen J; Lu Y; Lin K; Surh I; Fischer SM
Mol Oncol; 2014 Dec; 8(8):1626-39. PubMed ID: 25034079
[TBL] [Abstract][Full Text] [Related]
72. The impact of sphingosine kinase-1 in head and neck cancer.
Tamashiro PM; Furuya H; Shimizu Y; Iino K; Kawamori T
Biomolecules; 2013 Aug; 3(3):481-513. PubMed ID: 24970177
[TBL] [Abstract][Full Text] [Related]
73. Physiology and pathophysiology of prostanoid receptors.
Narumiya S
Proc Jpn Acad Ser B Phys Biol Sci; 2007 Dec; 83(9-10):296-319. PubMed ID: 24367153
[TBL] [Abstract][Full Text] [Related]
74. Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-mediated Pathway.
Chan WW; Mashimo H
J Neurogastroenterol Motil; 2013 Jul; 19(3):312-8. PubMed ID: 23875097
[TBL] [Abstract][Full Text] [Related]
75. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.
Jin J; Chang Y; Wei W; He YF; Hu SS; Wang D; Wu YJ
Acta Pharmacol Sin; 2012 May; 33(5):701-9. PubMed ID: 22555372
[TBL] [Abstract][Full Text] [Related]
76. The role of the EP receptors for prostaglandin E2 in skin and skin cancer.
Rundhaug JE; Simper MS; Surh I; Fischer SM
Cancer Metastasis Rev; 2011 Dec; 30(3-4):465-80. PubMed ID: 22012553
[TBL] [Abstract][Full Text] [Related]
77. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression.
Kim SH; Park YY; Kim SW; Lee JS; Wang D; DuBois RN
Cancer Res; 2011 Nov; 71(22):7010-20. PubMed ID: 21937683
[TBL] [Abstract][Full Text] [Related]
78. Selective activation of the prostaglandin E2 circuit in chronic injury-induced pathologic angiogenesis.
Liclican EL; Nguyen V; Sullivan AB; Gronert K
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6311-20. PubMed ID: 20610836
[TBL] [Abstract][Full Text] [Related]
79. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis.
Kamei D; Murakami M; Sasaki Y; Nakatani Y; Majima M; Ishikawa Y; Ishii T; Uematsu S; Akira S; Hara S; Kudo I
Biochem J; 2009 Dec; 425(2):361-71. PubMed ID: 19845504
[TBL] [Abstract][Full Text] [Related]
80. Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells.
Kaneshiro T; Okumura M; Maalouf S; Uflacker A; Maruyama T; Kawamori T
Prostaglandins Other Lipid Mediat; 2009 Nov; 90(1-2):31-6. PubMed ID: 19647091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
